This trial is testing the combination of KRT-232, carfilzomib, lenalidomide, and dexamethasone to treat patients with relapsed or refractory multiple myeloma. KRT-232 works by blocking MDM2, a protein needed for cell growth, while the other drugs work to kill or stop the growth of cancer cells in different ways. This combination may work better than previous treatments.
- Multiple Myeloma
4 Primary · 12 Secondary · Reporting Duration: Up to 30 days after last dose
1 Treatment Group
Treatment (AMG 232, carfilzomib, lenalidomide, dexamethasone)
1 of 1
40 Total Participants · 1 Treatment Group
Primary Treatment: MDM2 Inhibitor KRT-232 · No Placebo Group · Phase 1
Who is running the clinical trial?
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Are there vacancies within this clinical experiment for new participants?
"According to the clinicaltrials.gov database, this medical investigation is currently enrolling participants. Having been first published on October 27th 2017 and edited lastly on November 26th 2022, it appears that recruitment is still open." - Anonymous Online Contributor
How many medical facilities are conducting this experiment?
"Currently, this experiment is registering patients in 5 cities; Austin, San Antonio and Sacramento are among them. To reduce necessitated trips to the trial site, it would be judicious to select a location that's closest to you." - Anonymous Online Contributor
What is the ultimate objective of this research endeavor?
"This clinical trial intends to gauge the efficacy of MDM2 inhibitor KRT-232 and AMG-232, assessing changes in laboratory test results (hematology and blood chemistry) over a 30 day period. The pharmacokinetic profile of both medications will be analysed with liquid chromatography/tandem mass spectrometric methods, utilizing descriptive statistics such as means, medians, standard deviations etc., along with graphical summaries where appropriate. In addition, overall survival and complete response rates for each drug will be assessed using Kaplan-Meier methods and two sided 95% exact binominal CI respectively." - Anonymous Online Contributor
Has the U.S. Food and Drug Administration granted its seal of approval to KRT-232, a MDM2 Inhibitor?
"The safety of MDM2 Inhibitor KRT-232 was rated at 1 by our team given the limited data about its efficacy and safety in human studies, as this is a Phase 1 trial." - Anonymous Online Contributor
What medical conditions is MDM2 Inhibitor KRT-232 commonly used to treat?
"KRT-232 is a MDM2 Inhibitor typically used to treat ophthalmia and sympathetic. Additionally, it can be recommended for treatment of branch retinal vein occlusion, macular edema, and those who have had at least two rounds of systemic chemotherapy." - Anonymous Online Contributor
Has the efficacy of KRT-232 as a MDM2 Inhibitor been investigated in any prior research?
"Initially examined in 2002, MDM2 Inhibitor KRT-232 has since been studied extensively with a total of 1514 trials conducted. Currently there are 754 ongoing studies on the drug, many based out of Austin, Texas." - Anonymous Online Contributor
How many individuals are involved in this trial's proceedings?
"Affirmative. Records hosted on clinicaltrials.gov disclose that this experiment, which was first published on October 27th 2017, is still recruiting patients. Approximately 40 participants are required from 5 different medical sites." - Anonymous Online Contributor